I am a psychiatrist serving as director of the Massachusetts General Hospital (MGH) Center for Addiction Medicine (CAM) and Associate Professor of Psychiatry at Harvard Medical School (HMS). I have conducted NIDA sponsored patient oriented addiction research (POAR) since 1999. From 2001-2006, I was supported by a NIDA K23 award that enabled me to earn a masters degree in public health and to conduct mentored clinical research in nicotine dependence treatment. In 2005, I was asked to direct the MGH CAM and began to build a thriving clinical research program and to spend significant time mentoring junior investigators. My research has focused on discovery of novel pharmacologic and behavioral treatments for nicotine dependence in those with and without major psychiatric illnesses. I currently serve as principal investigator (PI) for two NIDA R01 and one NIDA R21 grant awards and am Co-PI and Project PI for the NIDA U01 Cooperative Drug Discovery for the Treatment of Nicotine Addiction (CDDG-ND). I have established a group of fifteen junior investigators working collaboratively in the context of my funded research to translate recent advances in neuroscience to the study and treatment of addictions. I work in a rich environment for clinical research. I receive no institutional support for mentoring and will be required curtail my mentoring effort in order to assume significant clinical responsibilities beginning in 2011. The K24 award will protect time that would otherwise be diverted to clinical responsibilities to allow me to continue to provide intensive ongoing mentorship to junior investigators in POAR and to spend more effort attracting excellent junior researchers to POAR, while devoting 45% effort to conducting independent, peer-reviewed POAR to discover novel treatments for nicotine dependence. My long term career objectives are: 1) To improve outcomes for adults with nicotine dependence by developing and testing novel pharmacologic and behavioral interventions and developing algorithms to tailor these interventions to increase cessation rates and reduce relapse in individuals;2) To improve our knowledge base of how to effectively treat nicotine dependence in smokers with co-morbid mental illness;3) To develop therapies for nicotine dependence that act upon basic mechanisms such that they are effective for other addictive disorders;and 4) To contribute to the development of early career investigators in clinical addiction research by providing mentored research opportunities.
The specific aims to be accomplished during the period of the award are to 1) Develop specific expertise in clinical research applications of neuroimaging and genetics in order to enhance ongoing and future research in development and testing of novel treatments for prevention of relapse to smoking and development of a knowledge base to guide patient-centered nicotine dependence treatment. 2) Protect time for substantive mentoring of junior investigators. 3) Continue and extend involvement in POAR. To accomplish these goals, I will devote 20% effort to new training, 30% effort to substantive mentoring of junior investigators, and 45% effort to funded POAR.

Public Health Relevance

Each year over 430,000 people in the US die from smoking-related illness;the annual global mortality toll is over 5 million, and 500 million existing cigarette smokers will die of causes that could be prevented by treatment of their addiction to tobacco-delivered nicotine. This K24 award will support mentoring and training of talented clinical scientists to discover novel treatments for smoking cessation and prevention of relapse to smoking that would not otherwise be supported.

Agency
National Institute of Health (NIH)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
5K24DA030443-05
Application #
8720734
Study Section
AIDS Behavioral Research Subcommittee (NIDA)
Program Officer
Aklin, Will
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Evins, A Eden; Hoeppner, Susanne S; Schoenfeld, David A et al. (2016) Maintenance pharmacotherapy normalizes the relapse curve in recently abstinent tobacco smokers with schizophrenia and bipolar disorder. Schizophr Res :
Schuster, Randi Melissa; Hoeppner, Susanne S; Evins, A Eden et al. (2016) Early onset marijuana use is associated with learning inefficiencies. Neuropsychology 30:405-15
Roberts, Emmert; Eden Evins, A; McNeill, Ann et al. (2016) Efficacy and tolerability of pharmacotherapy for smoking cessation in adults with serious mental illness: a systematic review and network meta-analysis. Addiction 111:599-612
Gilman, Jodi M; Schuster, Randi M; Curran, Max T et al. (2016) Neural mechanisms of sensitivity to peer information in young adult cannabis users. Cogn Affect Behav Neurosci 16:646-61
Schuster, Randi Melissa; Hanly, Ailish; Gilman, Jodi et al. (2016) A contingency management method for 30-days abstinence in non-treatment seeking young adult cannabis users. Drug Alcohol Depend 167:199-206
Stoeckel, Luke E; Chai, Xiaoqian J; Zhang, Jiahe et al. (2016) Lower gray matter density and functional connectivity in the anterior insula in smokers compared with never smokers. Addict Biol 21:972-81
Otto, Michael W; Kredlow, M Alexandra; Smits, Jasper A J et al. (2016) Enhancement of Psychosocial Treatment With D-Cycloserine: Models, Moderators, and Future Directions. Biol Psychiatry 80:274-83
Thorndike, Anne N; Achtyes, Eric D; Cather, Corinne et al. (2016) Weight gain and 10-year cardiovascular risk with sustained tobacco abstinence in smokers with serious mental illness: a subgroup analysis of a randomized trial. J Clin Psychiatry 77:e320-6
Pachas, Gladys N; Gilman, Jodi; Orr, Scott P et al. (2015) Single dose propranolol does not affect physiologic or emotional reactivity to smoking cues. Psychopharmacology (Berl) 232:1619-28
Janes, Amy C; Pedrelli, Paola; Whitton, Alexis E et al. (2015) Reward Responsiveness Varies by Smoking Status in Women with a History of Major Depressive Disorder. Neuropsychopharmacology 40:1940-6

Showing the most recent 10 out of 29 publications